Breaking News
CytomX Therapeutics, Inc. (CTMX) Reports Net Loss for FY25
Q4 2025 loss at CytomX Therapeutics, Inc. (CTMX) widened to $0.20 per share GAAP, worse than the -$0.09 estimate (116.4% wider).